StockNews.com Downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to Hold

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

A number of other equities analysts have also weighed in on the stock. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. BMO Capital Markets reissued an “outperform” rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. JPMorgan Chase & Co. boosted their target price on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a report on Thursday, February 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $235.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $395.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, March 5th. Nine research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $216.12.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $145.79 on Friday. The firm has a market cap of $18.36 billion, a P/E ratio of -40.95 and a beta of 0.39. Alnylam Pharmaceuticals has a 1-year low of $143.50 and a 1-year high of $218.88. The company has a 50 day simple moving average of $151.09 and a two-hundred day simple moving average of $166.50.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.68) earnings per share. Equities analysts anticipate that Alnylam Pharmaceuticals will post -4.54 earnings per share for the current year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after acquiring an additional 287,064 shares during the period. Wellington Management Group LLP raised its stake in shares of Alnylam Pharmaceuticals by 6.0% in the third quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock valued at $1,139,074,000 after acquiring an additional 364,021 shares during the period. Capital International Investors raised its stake in shares of Alnylam Pharmaceuticals by 15.8% in the fourth quarter. Capital International Investors now owns 3,586,657 shares of the biopharmaceutical company’s stock valued at $686,641,000 after acquiring an additional 488,814 shares during the period. Capital Research Global Investors raised its stake in shares of Alnylam Pharmaceuticals by 5.3% in the fourth quarter. Capital Research Global Investors now owns 2,930,079 shares of the biopharmaceutical company’s stock valued at $560,880,000 after acquiring an additional 146,236 shares during the period. Finally, Norges Bank purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $390,438,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.